Cooperation partner of the Inst. of Clinical Physiology

Priv.-Doz.* Dr. med.
Hans-Jörg Epple
e-mail
Orcid ID
 hans-joerg.epple{α}charite.de
 0000-0002-9901-1097


*Priv.-Doz. = Assistant professor (US), Lecturer (UK)
 

Research topics

Publications

 

Grants German Research Foundation (DFG)

2020

Günzel
et al.

DFG major instrumentation (Gro?er?, 700 T€) STED superresolution confocal microscope, consortium project: Epple HJ, Schneider T
2017 - 2022

Epple,
Schneider

Project C4 "Macromolecule uptake across the mucosa in HIV infection", in:
DFG Research Training Group (GRK 2318) "Tight junctions and their proteins: molecular features and actions in health and disease (TJ-Train)"

CV

1985 - 1992

Study of Medicine Karl-Rupprechts-Universität Heidelberg and Freie Universität Berlin
1992 - 1993 Doctoral thesis "Experimentelle Untersuchungen zum Mechanismus der mineralocorticoiden Wirkung von Carbenoxolon am menschlichen Dickdarm in vitro", Dept. of Clinical Physiology, Freie Universität Berlin (supervision: Prof. M. Fromm)
1993 - 1995 Internship, Medical Clinic, Department for Internal Medicine / Gastroenterology, Klinikum Steglitz, Freie Universität Berlin (Director: Prof. E. O. Riecken)
06/1995 Approbation
1995 - 2007 Residency, Department for Internal Medicine / Gastroenterology, Klinikum Steglitz, Freie Universität Berlin (Director: Prof. Dr. E. O. Riecken) and Medical Clinic Gastroenterology, Infectious Diseases, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin (Director: Prof. M. Zeitz)
2006 Specialist in Internal Medicine (Facharztanerkennung)
2007 Specialist for Infectious Diseases (Deutsche Gesellschaft für Infektiologie, Zusatzweiterbildung Ärztekammer Berlin)
since 2007 Consultant (Oberarzt) Medical Clinic Gastroenterology, Infectious Diseases, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin (Director: Prof. M. Zeitz
2011 Habilitation in Internal Medicine. Habilitation thesis on barrier function in infections of the intestinal mucosa ("Einfluss lokaler und systemischer mukosaler Infektionen auf Barrierefunktion und Immunsystem der Darmschleimhaut")